IO Biotech, Inc.
IOBT
$0.64
$0.011.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.72% | 4.35% | 2.30% | 0.33% | 4.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.53% | 6.21% | 4.11% | 4.08% | 15.26% |
| Operating Income | 4.53% | -6.21% | -4.11% | -4.08% | -15.26% |
| Income Before Tax | -0.35% | -18.06% | -11.01% | -10.34% | -13.38% |
| Income Tax Expenses | -170.69% | 30.58% | 36.35% | 69.37% | -9.08% |
| Earnings from Continuing Operations | 2.20% | -18.16% | -11.25% | -10.93% | -12.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.20% | -18.16% | -11.25% | -10.93% | -12.96% |
| EBIT | 4.53% | -6.21% | -4.11% | -4.08% | -15.26% |
| EBITDA | 4.54% | -6.22% | -4.09% | -4.05% | -15.28% |
| EPS Basic | 2.35% | -9.70% | 19.65% | 32.77% | 44.15% |
| Normalized Basic EPS | -0.19% | -9.39% | 19.68% | 32.88% | 43.66% |
| EPS Diluted | 2.35% | -9.70% | 19.65% | 32.77% | 44.15% |
| Normalized Diluted EPS | -0.19% | -9.39% | 19.68% | 32.88% | 43.66% |
| Average Basic Shares Outstanding | 0.40% | 6.34% | 25.04% | 51.73% | 92.90% |
| Average Diluted Shares Outstanding | 0.40% | 6.34% | 25.04% | 51.73% | 92.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |